+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 66 Pages
  • October 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5189135
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes.

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 1 and 3 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Acute Lymphoblastic Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection, Liver Transplant Rejection, Medulloblastoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma and Recurrent Medulloblastoma.

The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2020, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
  • The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
  • Report Coverage

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development
  • Helocyte Biosciences Inc
  • Hookipa Pharma Inc
  • Immunomic Therapeutics Inc
  • Moderna Inc
  • VBI Vaccines Inc

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

cytomegalovirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

cytomegalovirus vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

HB-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ITI-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ITI-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

mRNA-1443 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Triplex - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

VBI-1901 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant ProductsHuman cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020
  • Sep 14, 2020: VBI Vaccines to present additional biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
  • Sep 01, 2020: Immunomic Therapeutics announces publication of results from 3 ATTAC studies of CMV-specific dendritic cell vaccines for the treatment of GBM
  • Jun 22, 2020: HOOKIPA announces positive Phase 2 interim safety and immunogenicity results for its CMV vaccine candidate HB-101
  • Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified
  • May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
  • Apr 21, 2020: HOOKIPA Pharma announces publication of HB-101 Phase 1 results in The Journal of Infectious Diseases
  • Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901
  • Mar 03, 2020: Immunomic Therapeutics announces completion of pre-IND meeting with US FDA for ITI-1001, a vaccine for the treatment of GBM
  • Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients
  • Feb 10, 2020: City of Hope’s Triplex vaccine reduces rate of CMV complications in transplant recipients by 50 percent and spurs immunity against the virus
  • Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
  • Nov 21, 2019: Immunomic Therapeutics’ Collaborator, University of Florida presents new clinical data from ATTAC-II study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting
  • Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
  • Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Helocyte Biosciences Inc, H2 2020
  • Pipeline by Hookipa Pharma Inc, H2 2020
  • Pipeline by Immunomic Therapeutics Inc, H2 2020
  • Pipeline by Moderna Inc, H2 2020
  • Pipeline by VBI Vaccines Inc, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Helocyte Biosciences Inc
  • Hookipa Pharma Inc
  • Immunomic Therapeutics Inc
  • Moderna Inc
  • VBI Vaccines Inc